| 2025-11-14 |
详情>>
股本变动：
变动后总股本3103.79万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.16美元,归母净利润431.60万美元,同比去年增长109.33%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘后发布财报
|
| 2025-10-01 |
详情>>
内部人交易：
Jin David股份增加2711.00股
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益0.02美元,归母净利润64.00万美元,同比去年增长102.05%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.48美元,归母净利润-1271.5万美元,同比去年增长28.29%
|
| 2025-04-28 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.The election of seven directors for a term of one year;
2.The ratification of the Company’s appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.An advisory vote to approve the compensation of our named executive officers;
4.An advisory vote to approve the frequency with which we will hold an advisory vote on the compensation of our named executive officers;
5.The approval of the Second Amended and Restated Certificate of Incorporation, to provide for, among other things, officer exculpation;
6.The transaction of any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-2.69美元,归母净利润-5589万美元,同比去年增长18.61%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.43美元,归母净利润-4623.8万美元,同比去年增长19.42%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.76美元,归母净利润-3119.9万美元,同比去年增长38.01%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-1.03美元,归母净利润-1773.1万美元,同比去年增长24.69%
|
| 2024-04-05 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.The election of eight directors for a term of one year;
2.The ratification of the Company’s appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.The amendment of the Company’s 2013 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s common stock issuable thereunder by 10,000,000 and increase the annual share limit for participants pursuant to grants of stock options and stock appreciation rights;
4.The amendment of the Company’s 2012 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company’s common stock issuable thereunder by 1,000,000 and increase the number of shares eligible for purchase during an “Offering”;
5.The amendment of the Company’s Amended and Restated Long Term Incentive Plan to extend the term of the plan to July 15, 2035 and make certain related changes;
6.The transaction of any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-8.47美元,归母净利润-6866.9万美元,同比去年增长27.42%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-7.94美元,归母净利润-5738.2万美元,同比去年增长12.60%
|
| 2023-10-10 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2023-08-25 |
股东大会：
将于2023-10-09召开股东大会
会议内容 ▼▲
- 1.Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse split of our issued and outstanding common stock at a ratio of not less than 5-for-1 and not greater than 15-for-1, such ratio to be determined by our Board, at any time prior to October 24, 2023, the implementation and timing of which shall be subject to the discretion of our Board;
2.Transact any other business that may properly come before the Special Meeting or any adjournment of the Special Meeting.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.47美元,归母净利润-5032.9万美元,同比去年增长-22.36%
|
| 2023-04-28 |
股东大会：
将于2023-06-21召开股东大会
会议内容 ▼▲
- 1.The election of nine directors for a term of one year;
2.The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.The amendment of the Company’s 2013 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s common stock issuable thereunder by 7,000,000 and extend the term of the plan to December 31, 2033;
4.The amendment of the Company’s 2012 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company’s common stock issuable thereunder by 1,000,000;
5.The transaction of any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2023-03-13 |
股东大会：
将于2023-04-10召开股东大会
会议内容 ▼▲
- 1.The issuance of the rights and Contingent Subsidiary Securities in order to satisfy the requirements of Nasdaq Listing Rule 5635(c);
2.The transaction of any other business that may properly come before the Special Meeting or any adjournment of the Special Meeting.
|
| 2022-05-02 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.Elect eight directors for a term of one year;
2.An advisory vote to approve the compensation of our named executive officers;
3.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2022;
4.Amend the Amended and Restated Certificate of Incorporation, as amended, of the Company (the “Certificate of Incorporation”) in Article IV, Section A, to increase the number of authorized shares of the Company’s Common Stock from 170,000,000 to 200,000,000;
5.Amend the Company’s 2013 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s Common Stock issuable thereunder by 3,000,000;
6.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.Elect eight directors for a term of one year;
2.Amend the Amended and Restated Certificate of Incorporation, as amended, of the Company (the “Certificate of Incorporation”) in Article IV, Section A, to increase the number of authorized shares of the Company’s Common Stock from 150,000,000 to 170,000,000;
3.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2021;
4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2020-10-12 |
复牌提示：
2020-10-12 09:31:14 停牌，复牌日期 2020-10-12 09:36:14
|
| 2020-06-02 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.Elect eight directors for a term of one year;
2.Amend the Amended and Restated Certificate of Incorporation, as amended, of the Company (the “Certificate of Incorporation”) in Article IV, Section A, to increase the number of authorized shares of the Company’s Common Stock from 100,000,000 to 150,000,000;
3.Amend the Certificate of Incorporation, in Section 2(b) of the Certificate of Designations of the Rights and Preferences (the “Certificate of Designations”) of the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) to change the dividend payment date from quarterly to monthly on the Business Day closest but not beyond the end of each calendar month;
4.Amend the Company’s 2013 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s Common Stock issuable thereunder from 10,000,000 to 13,000,000;
5.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2020;
6.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2019-04-30 |
股东大会：
将于2019-06-18召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.An advisory vote to approve the compensation of our named executive officers;
4.An advisory vote on the frequency of the advisory vote on compensation of our named executive officers,
5.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2018-04-30 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.Approve an amendment to our 2012 Employee Stock Purchase Plan to increase the number of authorized shares issuable thereunder by 600,000 shares;
4.Approve our Second Amended and Restated Certificate of Incorporation which removes the Series A Preferred Stock designation set forth in the charter, leaving only the Series A Perpetual Preferred Designation and returns all other preferred shares previously designated to the “blank check preferred” reserve,
5.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2017-04-26 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve until the Company’s next annual meeting or until their successors have been elected and qualified;
2.To approve an amendment to the Company’s 2012 Employee Stock Purchase Plan to, among other things, reserve an additional 200,000 shares of common stock for issuance thereunder;
3.To approve the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan;
4.To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
5.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve until the Company’s next annual meeting or until their successors have been elected and qualified;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2015-06-04 |
股东大会：
将于2015-07-15召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve until the Company’s next annual meeting or until their successors have been elected and qualified;
2.To approve an amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan to reserve an additional 7,700,000 shares of common stock for issuance thereunder;
3.To approve the Fortress Biotech, Inc. Long Term Incentive Plan;
4.To hold an advisory vote on executive compensation;
5.To hold an advisory vote on the frequency with which future advisory votes on executive compensation should be held;
6.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015;
7.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|